Myelomas Cancer Treatment in India - Multiple myelomas arise from plasma cells and do not represent a single disease entity, but rather encompass a large number of subtypes with diverse natural histories

Multiple Myelomas

The simplest definition of multiple myelomas is that they are a form of a cancer, which arises from a single blood cell in the bone marrow, called the plasma cells. The plasma cells that become cancerous are termed myeloma cells. Myelomas do not represent a single disease entity, but rather encompass a large number of subtypes with diverse natural histories, from those that remain indolent for long periods to those that grow rapidly, and can prove fatal very quickly if untreated.


There are four subtypes of multiple myeloma (typically referred to as simply myeloma or plasma cell myeloma; also known as myelomatosis), dependent on the type of monoclonal protein produced. Each type appears to be associated with a different disease pattern; for example, IgA myeloma is associated with more organ damage, such as in the kidneys, than bone disease. About 50 per cent of patients with myeloma have cytogenetic abnormalities. The bone marrow often contains in excess of 30 per cent plasma cells. Rarely a variant of myeloma, called smoldering myeloma is diagnosed when the plasma cells in the bone marrow are between 10 and 30 per cent and no other findings of myeloma are present.

Treatment of Myelomas Cancer at World Class Cancer Hospital in India

  • ** PLEASE DESCRIBE THIS IMAGE **Newly diagnosed myeloma patient with symptoms: Our enhanced understanding of myeloma biology has led to important treatment changes over the past fifteen years. Prior to this, the treatment of the newly diagnosed patient with myeloma and those who have relapsed or have treatment refractory disease, comprised of cytotoxic chemotherapy and steroids with a modest benefit. There was some improvement with high-dose drug regimens followed by an autologous Stem Cell Transplant (SCT) (also known as an autograft). The recent availability of novel drugs, such as thalidomide (Thalomid), bortezomib (Velcade), and lenalidomide (Revlimid) has improved the overall survival, though long-term remissions and possible cure are rare. Potential cure can be accorded in some patients who are suitable for an allogenic SCT, but there is a significant risk of morbidity and mortality associated with this procedure.

  • Relapsed and refractory multiple myeloma: Relapse is defined as the reappearance of detectable paraprotein or other manifestation of disease in patients previously in CR. Progression is defined as an increase of 25 per cent in serum or urinary protein, or on the basis of increasing marrow infiltration, skeletal disease, and/or hypercalcemia (high calcium). All three novel agents, thalidomide, bortezomib, and lenalidomide are now widely approved in most countries for the treatment of patients with relapsed and refractory myeloma. Other novel strategies currently being pursued include the use of another thalidomide analogue, pomalidomide (Actmid), next generation proteasome inhibitors, carfilzomib (PR- 171), and arsenic trioxide.

  • Specialists will have a structured management plan for patients with symptomatic myeloma comprising specific supportive care to control symptoms, and also to minimise the risks of myelomarelated complications, such as bone disease and kidney failure, in addition to specific anti-myeloma therapy. Since the disease remains incurable at present, most specialists tend to offer treatment only to patients who become symptomatic.

The Future

** PLEASE DESCRIBE THIS IMAGE **Despite the remarkable progress made, sadly, most patients with myeloma remain incurable today. Current efforts are testing various combinations of novel drugs with diverse principal mechanisms of action.

Efforts are also being directed towards developing anti-myeloma vaccines, based on the qualified success of allogeneic stem cell transplantation in achieving long-term remissions and potential cure.

Some factors that may increase your risk of multiple myeloma include:

  • Age: The risk of multiple myeloma goes up with age. Less than one per cent of cases are diagnosed in people younger than 35. Most people diagnosed with this cancer are over 65 years old.

  • Gender: Men are slightly more likely to develop multiple myeloma than women.

  • Radiation: Exposure to radiation may increase the risk of multiple myeloma. At most, this accounts for a very small number of cases.

  • Family history: Multiple myeloma does seem to run in some families. Someone who has a sibling or parent with myeloma is four times more likely to get it than would be expected.

  • Workplace exposures: Some studies have suggested that workers in certain petroleum-related industries may be at a higher risk.

  • Other plasma cell diseases

Write to us for a Free No Obligation Opinion and Cost Estimate for Myelomas Cancer Treatment from Top Doctors in India
Please scan and email your medical reports to us at or and we shall get you a Free, No Obligation Opinion from India's Best Cancer Specialists

Name :  
City :  
E-mail :  
Phone :  
Please describe briefly your present medical condition
What medical procedure or service you want an opinion or estimate for?
I have read the disclaimer statement, please send me an opinion.
Please Click below on I'm not a robot
Note : If you are unable to submit this form for some reason please send us the details by email to


Prostate Cancer Surgery"I was looking for good cancer hospital for my prostate cancer treatment. I Wanted to get treated by good doctors and I did not want to pay huge amount.I started researching for cancer hospital in different countries which can provide me good treatment at reasonable cost."

Yasar, Nigeria Prostate Cancer Surgery

top-cancer-doctors-in-india top cancer doctors in india world class cancer technology in india
Breast Cancer

Breast cancer Treatment using latest & advanced technology

Prostate Cancer

The treatment options for prostate cancer depends on various factors like age, overall health of the patient and to what extent the tumor has spread.

Endometrial Cancer

Post- menopausal bleeding, but it is most likely an indicator of endometrial cancer

Leukemia Cancer

Cancer occurs when there is uncontrolled abnormal cell growth and development.

Lung Cancer

Are you aware that it is the leading cause of cancer death in the world?

Ovarian Cancer

A woman's lifetime risk of dying from ovarian cancer is 1.1 per cent.

Pancreatic Cancer

Problems in early detection and treatment failures render pancreatic cancer a gloomy prognosis

World's Most Advanced Technology for Cancer Treatment at World Class
Cancer Hospitals in India